OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Cancer Journal is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation	397
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	187
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	164
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	116
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	112
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience	109
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	105
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	98
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	93
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	85
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	85
Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort	82
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	79
Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis	76
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	66
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	64
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	63
Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors	63
Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma	62
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	61
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	60
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	57
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	56
Disparities in time to treatment with oral antimyeloma medications	56
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	56

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	55
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	54
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL	53
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	53
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	52
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia	51
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	50
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	50
Molecular variants, clonal evolution and clinical relevance in pediatric and adult T-cell lymphoblastic neoplasia	48
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	47
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	45
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	44
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	43
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression	43
Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study	42
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies	42
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	42